ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0323

Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group

Nevin Hammam1, Mohamed Bakrey Mahmoud2, Aly Bakhiet3, Rasha El Owaidy4, Hend Abdel Nabi5, Ahmed M Elsaman6, Iman Khalifa7, Abeer M NourEl-Din8, Rawhya R ElShereef9, Eman Hassan10, Faten Ismail9, Iman I El-Gazzar11, Abdelhafeez Moshrif12, Noha M Khalil13, Marwa A Amer14, Hanan M Fathy15, Nancy Abdel Salam15, Samar Tharwat16, Mervat I Abd Elazeem17, Hanan M Fathi18 and Tamer A Gheita11, 1Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 2Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, 3Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, 4Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, 5Pediatrics Department, Rheumatology and Nephrology Unit, Tanta University, Gharbia, Egypt, 6Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, 7Pediatrics Department, Rheumatology and Nephrology Unit, Helwan University, Cairo, Egypt, 8Pediatrics Department, National Research Centre (NRC), Cairo, Egypt, 9Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, 10Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, 11Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 12Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, 13Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, 14Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, 15Pediatrics Department, Rheumatology and Nephrology Unit, Alexandria University, Alexandria, Egypt, 16Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, 17Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, 18Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt

Meeting: ACR Convergence 2022

Keywords: Lupus nephritis, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ involvement patterns in patients with J-SLE may facilitate making accurate individualized management decisions. Therefore, we examined the clinical patterns of organ manifestations in patients with J-SLE by using cluster analysis and compared the frequency of various clinical features including lupus nephritis (LN), laboratory variables, and immunosuppressive therapies among these clusters of patients.

Methods: Patients (≤18 years) have a confirmed diagnosis of J-SLE by SLICC classification criteria were identified from the clinical database of the Egyptian College of Rheumatology (ECR) SLE study group (Eesa NN, et al. Lupus 2021). The demographic data, clinical characteristics, disease activity score, disease damage index, autoantibodies, and current therapies were selected. Patients were divided into groups by using the K-mean cluster analysis. After clustering, distinct J-SLE subtypes were identified and then validated by detect­ing significant differences across clusters. The Chi-square test was used for categorical variables and one-way ANOVA for continuous measures.

Results: Overall, 404 patients (355 (87.9%) female, mean age at diagnosis 11.2 years; mean disease duration 2.3 years) were included. Four distinct subsets of patients were identified with the characteristics of patients in each of these clusters summarized in Table 1, including the inter-cluster differences. The demographic characteristics and disease duration were comparable between groups (p > 0.05). Patients in cluster 1 (n=103, 25.5%) were characterized predominantly by mucocutaneous and neurologic manifestations. Patients in cluster 2 (n=101, 25.0%) were more likely to have arthritis and pulmonary manifestations. Cluster 3 was the smallest group (n=71, 17.6%), and patients in this group had the lowest prevalence of arthritis and LN, indicative of mild disease intensity. Patients in cluster 4 (n=129, 31.9%) have the highest prevalence of arthritis, vasculitis, renal involvement, and proliferative LN, Figure 1. The severity of the disease was different across clusters; patients in clusters 1 and 4 had the highest systemic lupus erythematosus disease activity index score, and lowest complement level, and were significantly less likely to use low dose aspirin (LDA). We found that autoantibodies positivity and SLE damage score were comparable across clusters.

Conclusion: We describe a large cohort of J-SLE and identify four distinct subgroups of patients using cluster analysis. The use of LDA appears to be associated with a mild severity form of the disease. Clustering analysis might help to implement targeted therapy for various disease subsets in heterogenous diseases like lupus. Further research to better understand the mechanistic pathways underlying different clinical phenotypes is needed.

Acknowledgment: The authors are grateful for Amany S El-Bahnasawy, Marwa ElKhalifa, Emad El-Shebini, Samah I Nasef, Nermeen Noshy, Nermeen Samy, Nouran M Abaza, Eman F Mohamed, Mohamed N Salem, Ahmed M Abdalla, Esam Abualfadl.

Supporting image 1

SD: standard deviation; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index; SLICC DI: Systemic Lupus Erythematosus International Collaborating Clinics Damage Index; WBCs: white blood cells, PLT: platelets, ESR: erythrocyte sedimentation rate; ANA: antinuclear antibody; anti-dsDNA: anti-double-stranded deoxyribonucleic acid antibody; and C: complement.
a Significantly different from cluster 1, b Significantly different from cluster 2, c Significantly different from cluster 3.

Supporting image 2

Mucocutaneous manifestations include malar rash, discoid rash, photosensitivity, and oral ulcer; Musculoskeletal manifestations include arthritis and myositis; Neurologic manifestations include depression, concentration problem, chorea, seizure, lupus headache, and peripheral neuropathy; Gastrointestinal manifestations include abdominal pain, hepatomegaly, elevated transaminase, and autoimmune hepatitis; Cardiovascular manifestations include pericarditis, myocarditis, endocarditis, and valvular insufficiency; Pulmonary manifestations include pleurisy/pleural effusion and pulmonary infiltrates; and Lupus Nephritis according to the 2018 revised classification of the International Society of Nephrology and the Renal Pathology Society.


Disclosures: N. Hammam, None; M. Bakrey Mahmoud, None; A. Bakhiet, None; R. El Owaidy, None; H. Abdel Nabi, None; A. M Elsaman, None; I. Khalifa, None; A. M NourEl-Din, None; R. R ElShereef, None; E. Hassan, None; F. Ismail, None; I. I El-Gazzar, None; A. Moshrif, None; N. M Khalil, None; M. A Amer, None; H. M Fathy, None; N. Abdel Salam, None; S. Tharwat, None; M. I Abd Elazeem, None; H. M Fathi, None; T. Gheita, None.

To cite this abstract in AMA style:

Hammam N, Bakrey Mahmoud M, Bakhiet A, El Owaidy R, Abdel Nabi H, M Elsaman A, Khalifa I, M NourEl-Din A, R ElShereef R, Hassan E, Ismail F, I El-Gazzar I, Moshrif A, M Khalil N, A Amer M, M Fathy H, Abdel Salam N, Tharwat S, I Abd Elazeem M, M Fathi H, Gheita T. Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identifying-distinct-phenotypes-of-patients-with-juvenile-systemic-lupus-erythematosus-results-from-a-cluster-analysis-by-the-egyptian-college-of-rheumatology-ecr-study-group/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-distinct-phenotypes-of-patients-with-juvenile-systemic-lupus-erythematosus-results-from-a-cluster-analysis-by-the-egyptian-college-of-rheumatology-ecr-study-group/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology